The impact of non-disclosure of HIV status and antiretroviral therapy on HIV recency testing and incidence algorithms
© 2024 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion..
BACKGROUND AND OBJECTIVES: Accurate HIV incidence estimates among blood donors are necessary to assess the effectiveness of programs aimed at limiting transfusion-transmitted HIV. We assessed the impact of undisclosed HIV status and antiretroviral (ARV) use on HIV recency and incidence estimates using increasingly comprehensive recent infection testing algorithms.
MATERIALS AND METHODS: Using 2017 donation data from first-time and lapsed donors, we populated four HIV recency algorithms: (1) serology and limiting-antigen avidity testing, (2) with individual donation nucleic amplification testing (ID-NAT) added to Algorithm 1, (3) with viral load added to Algorithm 2 and (4) with ARV testing added to Algorithm 3. Algorithm-specific mean durations of recent infection (MDRI) and false recency rates (FRR) were calculated and used to derive and compare incidence estimates.
RESULTS: Compared with Algorithm 4, progressive algorithms misclassified fewer donors as recent: Algorithm 1: 61 (12.1%); Algorithm 2: 14 (2.8%) and Algorithm 3: 3 (0.6%). Algorithm-specific MDRI and FRR values resulted in marginally lower incidence estimates: Algorithm 1: 0.19% per annum (p.a.) (95% confidence interval [CI]: 0.13%-0.26%); Algorithm 2: 0.18% p.a. (95% CI: 0.13%-0.22%); Algorithm 3: 0.17% p.a. (95% CI: 0.13%-0.22%) and Algorithm 4: 0.17% p.a. (95% CI: 0.13%-0.21%).
CONCLUSION: We confirmed significant misclassification of recent HIV cases when not including viral load and ARV testing. Context-specific MDRI and FRR resulted in progressively lower incidence estimates but did not fully account for the context-specific variability in incidence modelling. The inclusion of ARV testing, in addition to viral load and ID-NAT testing, did not have a significant impact on incidence estimates.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Vox sanguinis - (2024) vom: 15. Apr. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
van den Berg, Karin [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antiretroviral agents |
---|
Anmerkungen: |
Date Revised 16.04.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1111/vox.13627 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM371120543 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM371120543 | ||
003 | DE-627 | ||
005 | 20240416233621.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240416s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/vox.13627 |2 doi | |
028 | 5 | 2 | |a pubmed24n1377.xml |
035 | |a (DE-627)NLM371120543 | ||
035 | |a (NLM)38622931 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a van den Berg, Karin |e verfasserin |4 aut | |
245 | 1 | 4 | |a The impact of non-disclosure of HIV status and antiretroviral therapy on HIV recency testing and incidence algorithms |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 16.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a © 2024 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion. | ||
520 | |a BACKGROUND AND OBJECTIVES: Accurate HIV incidence estimates among blood donors are necessary to assess the effectiveness of programs aimed at limiting transfusion-transmitted HIV. We assessed the impact of undisclosed HIV status and antiretroviral (ARV) use on HIV recency and incidence estimates using increasingly comprehensive recent infection testing algorithms | ||
520 | |a MATERIALS AND METHODS: Using 2017 donation data from first-time and lapsed donors, we populated four HIV recency algorithms: (1) serology and limiting-antigen avidity testing, (2) with individual donation nucleic amplification testing (ID-NAT) added to Algorithm 1, (3) with viral load added to Algorithm 2 and (4) with ARV testing added to Algorithm 3. Algorithm-specific mean durations of recent infection (MDRI) and false recency rates (FRR) were calculated and used to derive and compare incidence estimates | ||
520 | |a RESULTS: Compared with Algorithm 4, progressive algorithms misclassified fewer donors as recent: Algorithm 1: 61 (12.1%); Algorithm 2: 14 (2.8%) and Algorithm 3: 3 (0.6%). Algorithm-specific MDRI and FRR values resulted in marginally lower incidence estimates: Algorithm 1: 0.19% per annum (p.a.) (95% confidence interval [CI]: 0.13%-0.26%); Algorithm 2: 0.18% p.a. (95% CI: 0.13%-0.22%); Algorithm 3: 0.17% p.a. (95% CI: 0.13%-0.22%) and Algorithm 4: 0.17% p.a. (95% CI: 0.13%-0.21%) | ||
520 | |a CONCLUSION: We confirmed significant misclassification of recent HIV cases when not including viral load and ARV testing. Context-specific MDRI and FRR resulted in progressively lower incidence estimates but did not fully account for the context-specific variability in incidence modelling. The inclusion of ARV testing, in addition to viral load and ID-NAT testing, did not have a significant impact on incidence estimates | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a HIV disclosure | |
650 | 4 | |a HIV incidence estimation | |
650 | 4 | |a HIV recency algorithms | |
650 | 4 | |a antiretroviral agents | |
650 | 4 | |a blood donation | |
700 | 1 | |a Murphy, Edward L |e verfasserin |4 aut | |
700 | 1 | |a Maartens, Gary |e verfasserin |4 aut | |
700 | 1 | |a Louw, Vernon J |e verfasserin |4 aut | |
700 | 1 | |a Grebe, Eduard |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Vox sanguinis |d 1952 |g (2024) vom: 15. Apr. |w (DE-627)NLM000095028 |x 1423-0410 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:15 |g month:04 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/vox.13627 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 15 |c 04 |